Cullinan Therapeutics, Inc.

CGEM Nasdaq SEC CIK 1789972
Follow Cullinan Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$49.4M +2.4% vs same quarter last year
EPS, diluted -
Operating cash flow −$43.1M −16.8% vs same quarter last year
Operating income −$52.6M +5.4% vs same quarter last year
Net income by quarter
−$47.8M
−$48.5M
−$70.1M
−$50.6M
−$50.7M
−$49.7M
−$53.7M
−$49.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$219.9M
FY24-−$167.6M
FY23-−$155.1M
FY22$0$111.2M
FY21$18.9M−$65.6M
FY20$0−$51.8M
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$175.8M
FY24−$145.3M
FY23−$134.5M
FY22−$127.8M
FY21−$43.4M
FY20−$29.8M
FY19-